222 related articles for article (PubMed ID: 37293562)
21. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents.
Kelloff GJ; Crowell JA; Steele VE; Lubet RA; Malone WA; Boone CW; Kopelovich L; Hawk ET; Lieberman R; Lawrence JA; Ali I; Viner JL; Sigman CC
J Nutr; 2000 Feb; 130(2S Suppl):467S-471S. PubMed ID: 10721931
[TBL] [Abstract][Full Text] [Related]
22. Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemoprevention study.
Benner SE; Winn RJ; Lippman SM; Poland J; Hansen KS; Luna MA; Hong WK
J Natl Cancer Inst; 1993 Jan; 85(1):44-7. PubMed ID: 8416256
[TBL] [Abstract][Full Text] [Related]
23. Current status of chemoprevention of head and neck cancer.
Benner SE; Lippman SM; Hong WK
Oncology (Williston Park); 1992 Aug; 6(8):61-6; discussion 66-8, 71 passim. PubMed ID: 1386997
[TBL] [Abstract][Full Text] [Related]
24. Chemoprevention strategies for pancreatic cancer.
Stan SD; Singh SV; Brand RE
Nat Rev Gastroenterol Hepatol; 2010 Jun; 7(6):347-56. PubMed ID: 20440279
[TBL] [Abstract][Full Text] [Related]
25. Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.
Holpuch AS; Desai KG; Schwendeman SP; Mallery SR
J Carcinog; 2011; 10():23. PubMed ID: 22013393
[TBL] [Abstract][Full Text] [Related]
26. Chemoprevention of oral cancer: Green tea experience.
Ramshankar V; Krishnamurthy A
J Nat Sci Biol Med; 2014 Jan; 5(1):3-7. PubMed ID: 24678188
[TBL] [Abstract][Full Text] [Related]
27. Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory.
Dionne KR; Warnakulasuriya S; Zain RB; Cheong SC
Int J Cancer; 2015 Feb; 136(3):503-15. PubMed ID: 24482244
[TBL] [Abstract][Full Text] [Related]
28. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
Armstrong WB; Kennedy AR; Wan XS; Atiba J; McLaren CE; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):43-7. PubMed ID: 10667462
[TBL] [Abstract][Full Text] [Related]
29. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.
Armstrong WB; Taylor TH; Kennedy AR; Melrose RJ; Messadi DV; Gu M; Le AD; Perloff M; Civantos F; Goodwin WJ; Wirth LJ; Kerr AR; Meyskens FL
Cancer Prev Res (Phila); 2013 May; 6(5):410-8. PubMed ID: 23639862
[TBL] [Abstract][Full Text] [Related]
30. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer.
Zaridze D; Evstifeeva T; Boyle P
Ann Epidemiol; 1993 May; 3(3):225-34. PubMed ID: 8275193
[TBL] [Abstract][Full Text] [Related]
31. Oral Pre-malignancy: An Update on Novel Therapeutic Approaches.
Naara S; Andrews C; Sikora A; Williams M; Chambers M; Myers J; Amit M
Curr Oncol Rep; 2024 Jun; ():. PubMed ID: 38865005
[TBL] [Abstract][Full Text] [Related]
32. New agents for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet RA; Doody LA; Malone WF; Hawk ET; Sigman CC
J Cell Biochem Suppl; 1996; 26():1-28. PubMed ID: 9154166
[TBL] [Abstract][Full Text] [Related]
33. Leukoplakia and Immunology: New Chemoprevention Landscapes?
Grigolato R; Bizzoca ME; Calabrese L; Leuci S; Mignogna MD; Lo Muzio L
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961682
[TBL] [Abstract][Full Text] [Related]
34. Topical application of vitamin A to oral leukoplakia: A clinical case series.
Epstein JB; Gorsky M
Cancer; 1999 Sep; 86(6):921-7. PubMed ID: 10491516
[TBL] [Abstract][Full Text] [Related]
35. A comparative study to evaluate the therapeutic effects of nutraceuticals in oral leukoplakia:- A randomized clinical trail.
Ahmad T; Khan I; Sultana A; Rizvi MMA
Natl J Maxillofac Surg; 2023; 14(3):413-419. PubMed ID: 38273920
[TBL] [Abstract][Full Text] [Related]
36. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment.
Sankaranarayanan R; Mathew B; Varghese C; Sudhakaran PR; Menon V; Jayadeep A; Nair MK; Mathews C; Mahalingam TR; Balaram P; Nair PP
Oral Oncol; 1997 Jul; 33(4):231-6. PubMed ID: 9307711
[TBL] [Abstract][Full Text] [Related]
37. An overview of effect of lycopene and curcumin in oral leukoplakia and oral submucous fibrosis.
Ahmad T; Khan I; Rizvi MM; Saalim M; Manzoor N; Sultana A
Natl J Maxillofac Surg; 2021; 12(3):316-323. PubMed ID: 35153425
[TBL] [Abstract][Full Text] [Related]
38. Chemoprevention of nonmelanoma skin cancer.
Wright TI; Spencer JM; Flowers FP
J Am Acad Dermatol; 2006 Jun; 54(6):933-46; quiz 947-50. PubMed ID: 16713450
[TBL] [Abstract][Full Text] [Related]
39. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials.
William WN; Papadimitrakopoulou VA
Cancer Prev Res (Phila); 2013 May; 6(5):375-8. PubMed ID: 23639861
[TBL] [Abstract][Full Text] [Related]
40. Intervention efficacy and malignant transformation to oral cancer among patients with leukoplakia (Review).
Shiu MN; Chen TH
Oncol Rep; 2003; 10(6):1683-92. PubMed ID: 14534680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
